C7A.1
Malignant poorly differentiated neuroendocrine tumors
Clinical Classification Guidelines
Inclusion Terms
- Malignant poorly differentiated neuroendocrine tumor NOS
- Malignant poorly differentiated neuroendocrine carcinoma, any site
- High grade neuroendocrine carcinoma, any site
Medical Intelligence & Overview
Malignant poorly differentiated neuroendocrine tumors, classified under ICD-10 code C7A.1, are a type of aggressive cancer that originates from neuroendocrine cells. These tumors are characterized by their high grade and aggressive nature, often spreading quickly to other parts of the body. They can occur at any site in the body but are most commonly found in the lungs, gastrointestinal tract, or pancreas. Recognizing the nature of these tumors is crucial for timely diagnosis and management.
Causes & Symptoms
Clinical Causes: Genetic mutations that alter cell growth and division Inherited genetic syndromes associated with neuroendocrine tumors Environmental factors such as exposure to carcinogens Chronic inflammation or infection at specific sites Previous history of other cancers or radiation therapy
Key Symptoms: Unexplained weight loss Persistent abdominal pain or discomfort Unusual fatigue or weakness Presence of a mass or lump in affected areas Symptoms related to hormone production if the tumor secretes hormones, such as flushing or diarrhea Respiratory symptoms if located in the lungs, like cough or shortness of breath Difficulty swallowing or changes in bowel habits depending on tumor location
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation and specialized tests, including:
Treatment Protocols: Treatment strategies for malignant poorly differentiated neuroendocrine tumors are often aggressive and may include:
Clinical Advice & FAQs
Billing Guidance
Is C7A.1 a billable ICD-10 code?
Yes, C7A.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C7A.1?
Clinical documentation must specify the nature of Malignant poorly differentiated neuroendocrine tumors and any associated comorbidities for accurate reporting.
Cite this Clinical Reference